- Home
- RNXT vs CGTX Comparison
RNXT vs CGTX Comparison
Compare RNXT & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RNXT | CGTX |
|---|---|---|
| Founded | 2012 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.4M | 158.8M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | RNXT | CGTX |
|---|---|---|
| Price | $0.96 | $1.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $7.75 | $2.88 |
| AVG Volume (30 Days) | 295.1K | ★ 942.9K |
| Earning Date | 11-13-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $928,000.00 | N/A |
| Revenue This Year | $2,795.35 | N/A |
| Revenue Next Year | $272.69 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.70 | $0.22 |
| 52 Week High | $1.69 | $3.83 |
Technical Indicators
Market Signals| Indicator | RNXT | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 51.82 | 53.10 |
| Support Level | $0.92 | $1.69 |
| Resistance Level | $0.93 | $1.77 |
| Average True Range (ATR) | 0.05 | 0.12 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 81.94 | 75.58 |
Price Performance
Historical ComparisonAbout RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.